Industry Concerned Over EMA Plan To Make More PIP Information Public

The European Medicines Agency’s plan to publish details of the studies and measures it agrees with a drug developer for a pediatric investigation plan will help other companies in framing their future marketing authorization applications. But there are concerns that the agency's plan might result in the disclosure of commercially confidential information.